Advocacy through groups like BCAN and the AUA shapes urologic oncology policy—driving funding, screening access, and equity in cancer care, the authors write.
News|Articles|October 3, 2025
FDA news recap in urologic oncology for Q3 2025
Fact checked by: Patrick Campbell
Here’s a look back at notable news between July and September 2025.
Advertisement
Advertisement
The third quarter of 2025 saw a flurry of activity in the urologic oncology space. Bladder cancer continues to generate substantial buzz, particularly with the September FDA approvals of gemcitabine intravesical system (Inlexzo; formerly TAR-200) in BCG-unresponsive non–muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors and pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex; Merck) for subcutaneous injection across all previously approved solid tumor indications of IV pembrolizumab in adults and adolescents (≥12 years).
Related to this article
The PDUFA target action date is in the fourth quarter of 2026.
The approval is supported by data from the phase 3 LITESPARK-011 trial.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
Better detection has changed prostate cancer care. Patients choosing radical treatment still need better protection from the disease returning.
Enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) showed the strongest EFS, OS, and PCR associations among neoadjuvant MIBC strategies in a network meta-analysis, although perioperative design limits attribution.
Sandip Prasad, MD, MPhil, discusses the evolving role of chemoablation in recurrent low-grade, intermediate-risk NMIBC, including patient selection and treatment considerations.
Eugene Cone, MD, discusses recombinant BCG for NMIBC, including ongoing clinical evaluation and its potential to address ongoing BCG supply challenges.
Advertisement
Advertisement